HeartSciences (NASDAQ:HSCS – Get Free Report) and Standard BioTools (NASDAQ:LAB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Analyst Recommendations
This is a summary of current ratings for HeartSciences and Standard BioTools, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
| Standard BioTools | 1 | 3 | 0 | 0 | 1.75 |
HeartSciences currently has a consensus target price of $9.20, indicating a potential upside of 206.67%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 20.54%. Given HeartSciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe HeartSciences is more favorable than Standard BioTools.
Risk and Volatility
Profitability
This table compares HeartSciences and Standard BioTools’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HeartSciences | N/A | -388.12% | -161.65% |
| Standard BioTools | -86.06% | -20.89% | -15.98% |
Insider and Institutional Ownership
17.2% of HeartSciences shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 1.8% of HeartSciences shares are held by insiders. Comparatively, 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares HeartSciences and Standard BioTools”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HeartSciences | N/A | N/A | -$8.77 million | ($6.88) | -0.44 |
| Standard BioTools | $174.43 million | 2.47 | -$138.88 million | ($0.34) | -3.29 |
HeartSciences has higher earnings, but lower revenue than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.
Summary
HeartSciences beats Standard BioTools on 7 of the 13 factors compared between the two stocks.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
About Standard BioTools
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
